Synergistic Effect of Ribitol and Shikonin Promotes Apoptosis in Breast Cancer Cells

Area of Science:

• Oncology
• Biochemistry
• Metabolomics

Background:

• Breast cancer mortality remains high despite chemotherapy advances.
• Novel therapeutic strategies are urgently needed.
• Targeting cancer cell metabolism offers a promising avenue.

Purpose of the Study:

• To investigate the synergistic effect of ribitol and shikonin on breast cancer cells.
• To explore the underlying mechanisms of this combined treatment.
• To identify potential new therapeutic approaches for breast cancer.

Main Methods:

• Screening of small molecules targeting energy metabolism in breast cancer.
• In vitro assessment of ribitol and shikonin combination therapy.
• Analysis of cell proliferation, apoptosis, and key protein expression (p53, c-Myc, Bcl-xL, Mcl-1).
• Metabolomic analysis to understand metabolic pathway involvement (Warburg effect, glycolysis, TCA cycle).

Main Results:

• Ribitol significantly enhanced shikonin's growth-inhibitory effects, demonstrating synergy.
• Combined treatment increased apoptosis by 56% (p < 0.01) compared to shikonin alone (38%).
• Significant cell proliferation arrest (40%, p < 0.01) and apoptosis induction were observed.
• Upregulation of p53 and downregulation of c-Myc, Bcl-xL, and Mcl-1 were noted.
• Metabolomic data indicated involvement of the Warburg effect, glycolysis, and TCA cycle dysregulation.

Conclusions:

• Ribitol selectively enhances the cytotoxic effects of shikonin against breast cancer in vitro.
• The combination therapy induces apoptosis and cell cycle arrest.
• Metabolic pathway modulation, including the Warburg effect, is a key mechanism.